Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogennews2022-12-29T19:54:35+00:00December 29th, 2022|The New York Times|
Alzheimer’s APOE4 Genetic Risk Targeted in Promising Trialnews2022-12-02T21:55:07+00:00December 2nd, 2022|The New York Times|
Alzheimer’s Drug May Benefit Some Patients, New Data Showsnews2022-11-30T00:50:06+00:00November 30th, 2022|The New York Times|
What A.L.S. and Alzheimer’s Drug Approvals Have in Commonnews2022-10-14T19:10:06+00:00October 14th, 2022|The New York Times|
Alzheimer’s Drug Slows Cognitive Decline in Key Studynews2022-09-28T13:42:59+00:00September 28th, 2022|The New York Times|
Trial of New Alzheimer’s Drug Reports Disappointing Resultsnews2022-06-16T22:25:55+00:00June 16th, 2022|The New York Times|
Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelmnews2022-05-03T18:00:36+00:00May 3rd, 2022|The New York Times|
Scientists Question Data Behind an Experimental Alzheimer’s Drugnews2022-04-19T00:48:52+00:00April 19th, 2022|The New York Times|
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trialsnews2022-04-07T23:32:59+00:00April 7th, 2022|The New York Times|
Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drugnews2022-04-06T18:43:00+00:00April 6th, 2022|The New York Times|
